Hydroxychloroquine Market Research and Forecast Report 2023-2028

1. Global Hydroxychloroquine Market Research and Forecast Report 2023-2028 Author: Elena Anderson, Marketing Manager | Copyright © IMARC Service Pvt Ltd. All Rights Reserved IMARC Group © 2019 IMARC All Rights Reserved

2. Report DescriptionAbout IMARC Group The International Market Analysis Research and Consulting Group is a leading adviser on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise. IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.

3. Report Description and Highlights Report Description Global Hydroxychloroquine Market Research Report: The latest report by IMARC, titled “Hydroxychloroquine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028” the global hydroxychloroquine market size reached US$ 1.3 Billion in 2022. Hydroxychloroquine (HCQ) is a medication that belongs to the class of drugs known as antimalarials, primarily used for treating and preventing malaria, a parasitic infection transmitted through mosquito bites. It works by interfering with the parasites' ability to survive and multiply in the body. In addition to this, hydroxychloroquine has shown efficacy in managing various autoimmune diseases. It is commonly prescribed for rheumatoid arthritis and lupus erythematosus, where the immune system mistakenly attacks healthy tissues and organs. HCQ helps suppress the overactivity of the immune system, reducing inflammation and alleviating symptoms associated with these autoimmune disorders. It is currently available in tablet and intravenous forms. It is well-absorbed by the body and reaches therapeutic levels relatively quickly. The dosage and duration of HCQ vary depending on the specific condition and individual patient factors. Request market/requestsample Free Sample Report: https://www.imarcgroup.com/hydroxychloroquine-

4. Report Description and Highlights Report Description Global Hydroxychloroquine Market Trends: The increasing prevalence of malaria around the world is fueling the demand for effective antimalarial drugs, such as hydroxychloroquine, primarily driving the market growth. Besides this, surging investments in the procurement and distribution of hydroxychloroquine by various government and healthcare organizations to combat this infectious disease are positively impacting the market growth. Moreover, the expanding product adoption for treating and managing autoimmune diseases, such as rheumatoid arthritis and lupus erythematosus, is presenting remunerative growth opportunities for the market. In addition to this, the growing use of hydroxychloroquine to treat porphyria cutanea tarda, where an individual suffers from painful and blistering skin due to sensitivity to sunlight, is acting as another significant growth-inducing factor. Furthermore, the extensive focus on research and development (R&D) activities in the thriving pharmaceutical sector to enhance the therapeutic applications of hydroxychloroquine is contributing to the market growth. Concurrent with this, ongoing studies investigating the potential use of the medication in conditions, such as cancer, human immunodeficiency virus (HIV), and viral infections, are aiding in market expansion. Looking forward, the market value is projected to reach US$ 2.0 Billion by 2028, expanding at a CAGR of 7.5% during 2023-2028. Looking forward, the market value is projected to reach a strong growth during the forecast period (2023-2028).

5. Report Description and Highlights Report Description Market Summary: Dosage Type Insights: • 200 Mg • 300 Mg • 400 Mg • Others Distribution Insights: • Hospital Pharmacies • Retail Pharmacies • Others Application Insights: • Rheumatoid Arthritis • Lupus Erythematosus • Malaria • Coronavirus (COVID-19) • Others

6. Report Description and Highlights Report Description Grade Insights: • USP Standards Grade • EP Standards Grade • Pharmaceutical Standards Grade • Others Route of Administration Insights: • Oral • Intravenous Regional Insights: • North America • United States • Canada • Asia Pacific • China • Japan • India • South Korea • Australia

7. Report Description and Highlights Report Description • Indonesia • Others • Europe • Germany • France • United Kingdom • Italy • Spain • Russia • Others • Latin America • Brazil • Mexico • Others • Middle East and Africa

8. Report Description and Highlights Report Description Competitive Landscape with Key Players: • • • • • • • • • • • • Amneal Pharmaceuticals Inc. Cipla Ltd. Ipca Laboratories Ltd. Laurus Labs Lupin Limited Mylan N.V. Prasco Laboratories Dr. Reddy’s Laboratories Ltd. Sanofi S.A. Teva Pharmaceuticals USA Inc. (Teva Pharmaceutical Industries Ltd.) Torrent Pharmaceuticals Ltd. Zydus Lifesciences Limited View Full Report with TOC & List of Figure: https://www.imarcgroup.com/hydroxychloroquine- market

9. We are the trusted business partners to the world's leading corporates, governments, and institutions Partial List of Clients A partial List of our Clients

10. We are the trusted business partners to the world's leading corporates, governments, and institutions Partial List of Clients A partial List of our Clients

11. Report Description and Highlights Report Description © 2019 IMARC All Rights Reserved This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC). Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication. IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.

12. Contact Us FOR MORE DETAILS Visit us at : https://www.imarcgroup.com Stay With Us: TELEPHONE: +1-631-791-1145 E-MAIL: sales@imarcgroup.com